DD3PCA3-based Molecular Urine Analysis for the Diagnosis of Prostate Cancer

Hessels, Daphne; Gunnewiek, Jacqueline M. T. Klein; Oort, Inge M. van; Karthaus, H. F. M.; Leenders, Geert J.L. van; Balken, Bianca van; Kiemeney, Lambertus A.; Witjes, J. Alfred; Schalken, Jack A.

doi:10.1016/s0302-2838(03)00201-x

Cited by 614 publications

(399 citation statements)

References 24 publications

Supporting

Mentioning

371

Contrasting

Unclassified

Order By: Relevance

“…10 Moreover, applying the more sensitive reverse transcriptase polymerase chain reaction (RT-PCR), no PCA3 DD3 transcripts could be detected in a wide range of human extraprostatic normal and cancerous tissues suggesting that PCA3 DD3 is the most specific prostate cancer gene identified to date. 11,12 The PCA3 DD3 mRNA includes a high density of stop codons; thus, it does not have an open reading frame resulting in a noncoding RNA. 12 The degree of specificity of the PCA3 DD3 test makes its incorporation into the prostate cancer diagnostic armamentarium highly desirable; however, quantitative RT-PCR techniques require a complex laboratory infrastructure thus rendering its routine clinical application impractical.…”

mentioning

confidence: 99%

“…11,12 The PCA3 DD3 mRNA includes a high density of stop codons; thus, it does not have an open reading frame resulting in a noncoding RNA. 12 The degree of specificity of the PCA3 DD3 test makes its incorporation into the prostate cancer diagnostic armamentarium highly desirable; however, quantitative RT-PCR techniques require a complex laboratory infrastructure thus rendering its routine clinical application impractical. Recently, an assay for qualitative simultaneous detection of PCA3 DD3 RNA and PSA mRNA as a marker for prostatic cells in urine samples has been introduced; it was designated as NASBA (nucleic acid sequence-based amplification), (uPM3, DiagnoCure, Quebec, Canada).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Prostate cancer detected by uPM3: radical prostatectomy findings

et al. 2006

View full text Add to dashboard Cite

uPM3 is the first urine-based genetic test that is highly specific for detecting prostate cancer. The histopathologic characteristics of uPM3-detected cancer in radical prostatectomy specimens have not been previously described. We evaluated a consecutive series of radical prostatectomies to determine the extent, zonal distribution and other features of prostate cancer following uPM3 detection. A total of 24 whole-mounted, totally embedded radical prostatectomy specimens were evaluated. All patients had clinically localized cancer and none received preoperative therapy. Zonal location of cancer, distance to the urethra, cancer volume, Gleason grade and multicentricity were recorded; volume of cancer was measured using the grid-counting method. Patients ranged in age from 43 to 75 years (mean 65 years). In 21/24 cases, cancer involved the transition and peripheral zones and was multicentric (87%). Mean cancer volume was 3.96 cm 3 (range 0.08-16.86 cm 3 ). Mean distance to the urethra was 0.50 cm for the closest cancer and 0.61 cm for the most distant cancer. Mean Gleason score was 7 (range 5-9); pathologic stage was pT2 for 17 cases and pT3 for seven cases. The uPM3 is an independent and specific biomarker that detects prostate cancers of similar volume, location, extent and grade as other tests for early detection. uPM3 does not preferentially identify large or aggressive prostate cancers. Keywords: uPM3; prostate; cancer; tumor volume; Gleason score; multicentricity Prostate carcinoma is the most common visceral cancer in men; it was estimated that in 2005 in the USA 232 090 new cases were diagnosed, and that 30 350 men died of the disease. 1 If prostate carcinoma is detected while still limited to its primary site, radical prostatectomy or radiotherapy is in most cases successful in controlling it; 2,3 thus, early diagnosis is a key element in its management.The specificity of the serum PSA test is not ideal; approximately 20% of men with PSA levels of 2.5-4 ng/ml will have prostatic carcinoma. 4-6 The PSA derivatives, for example, correlations of serum levels with prostatic volume, levels changes over time, and the addition of statistical methods improve the test's specificity but the underlying problems remain essentially unsolved. 7-9 Therefore, it is evident that more specific clinical markers for early prostate cancer are needed.The PCA3 DD3 gene is localized at chromosome 9q21-22; and by Northern blot analysis was noted to be up to 100 times overexpressed in 53/56 prostate cancers while it was not expressed in adjacent noncancerous prostate tissues. 10 Moreover, applying the more sensitive reverse transcriptase polymerase chain reaction (RT-PCR), no PCA3 DD3 transcripts could be detected in a wide range of human extraprostatic normal and cancerous tissues suggesting that PCA3 DD3 is the most specific prostate cancer gene identified to date. 11,12 The PCA3 DD3 mRNA includes a high density of stop codons; thus, it does not have an open reading frame resulting in a noncoding RNA. 12 The degree of specificit...

show abstract

mentioning

confidence: 99%

mentioning

confidence: 99%

Prostate cancer detected by uPM3: radical prostatectomy findings

et al. 2006

View full text Add to dashboard Cite

show abstract

“…35 The amplification products (after 35 cycles of PCR) were quantified by time-resolved fluorescence-based hybridization on streptavidin-coated microplates. Prostate tumors showed a 66-fold upregulation of PCA3 in more than 95% of cancer cases compared to benign prostate tissue.…”

Section: Prostate Cancer Antigenmentioning

confidence: 99%

Urine markers in monitoring for prostate cancer

Jamaspishvili

Král

Khomeriki

et al. 2009

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

The major advantages of urine-based assays are their noninvasive character and ability to monitor prostate cancer with heterogeneous foci. Almost all urine-detectable prostate-specific markers have been recently reviewed. For this reason, we focus here on only a few promising markers which have been independently evaluated (in particular PCA3, fusion genes, TERT, AMACR, GSTP1, MMP9 and VEGF) and very recent ones (ANXA3 and sarcosine). The emphasis is also on multiplex biomarker analysis and on microarray-based analysis of fusion genes. A combination of multiple urine biomarkers may be valuable in the case of men with persistently elevated serum prostatespecific antigen and a history of negative biopsies. The emerging urine tests should help in both early diagnosis of prostate cancer and identifying aggressive tumors for radical treatment.

show abstract

“…Prostate tumours showed a 66-fold upregulation of DD3 PCA3 when compared with benign prostatic tissue. 8 This upregulation was found in more than 95% of prostate cancer specimens studied. Therefore, this DD3 PCA3 -based RT-PCR assay was used for the identification of prostate cancer in urine sediments obtained after prostatic massage.…”

mentioning

confidence: 94%